概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线

格隆汇11-17

诺和诺德的减肥药诺和盈在国内上市迎来新进展。今日，诺和诺德宣布，全球首个且目前唯一用于长期体重管理的胰高糖素样肽﹣1受体激动剂(GLP-1)周制剂诺和盈正式在中国上市。据悉，诺和盈又被称为“减肥版”司美格鲁肽，能够实现平均约17%的体重降幅，其减重效果可以持续至少2年。诺和诺德透露，目前，诺和盈已在全球超过10个国家和地区上市。截至目前，司美格鲁肽已累积起超过2200万患者暴露年的使用经验。上海...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2484509265?lang=zh_CN&edition=full","thumbnail":"https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280","is_english":false,"pubTime":"2024-11-17 14:35","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2484509265","market":"hk","top_or_hot":-1,"title":"概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线","media":"格隆汇","content":"<div>\n<p>诺和诺德的减肥药诺和盈在国内上市迎来新进展。今日，诺和诺德宣布，全球首个且目前唯一用于长期体重管理的胰高糖素样肽﹣1受体激动剂(GLP-1)周制剂诺和盈正式在中国上市。据悉，诺和盈又被称为“减肥版”司美格鲁肽，能够实现平均约17%的体重降幅，其减重效果可以持续至少2年。诺和诺德透露，目前，诺和盈已在全球超过10个国家和地区上市。截至目前，司美格鲁肽已累积起超过2200万患者暴露年的使用经验。上海...</p>\n\n<a href=\"https://www.gelonghui.com/p/1336126\">网页链接</a>\n\n</div>\n","source":"gelonghui_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-17 14:35 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/p/1336126><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>诺和诺德的减肥药诺和盈在国内上市迎来新进展。今日，诺和诺德宣布，全球首个且目前唯一用于长期体重管理的胰高糖素样肽﹣1受体激动剂(GLP-1)周制剂诺和盈正式在中国上市。据悉，诺和盈又被称为“减肥版”司美格鲁肽，能够实现平均约17%的体重降幅，其减重效果可以持续至少2年。诺和诺德透露，目前，诺和盈已在全球超过10个国家和地区上市。截至目前，司美格鲁肽已累积起超过2200万患者暴露年的使用经验。上海...</p>\n\n<a href=\"https://www.gelonghui.com/p/1336126\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688076","symbol_name":"诺泰生物","start_time":0,"source_url":"https://www.gelonghui.com/p/1336126","article_id":"2484509265","we_media_id":null,"thumbnails":["https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484509265","pubTimestamp":1731825344,"columns":[],"sourceInfo":{"source_id":"gelonghui_highlight","name":"格隆汇"},"weMediaInfo":null,"summary":"市场前景广阔","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300003":"乐普医疗","300199":"翰宇药业","600276":"恒瑞医药","603456":"九洲药业","688076":"诺泰生物","688117":"圣诺生物","01801":"信达生物","BK0239":"医药制造","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0183":"MSCI概念","BK0012":"证金概念","BK0196":"行业龙头","BK0077":"质押式回购","NVO":"诺和诺德","BK0132":"高送转概念","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK0060":"抗癌","BK4532":"文艺复兴科技持仓","BK0042":"基因检测","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK0114":"健康中国","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK0028":"国家队","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4007":"制药","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0201":"可转债","BK0113":"养老产业","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","002821":"凯莱英","BK4588":"碎股","BK0070":"员工持股","BK0188":"融资融券","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK0251":"专用设备"},"translate_title":"Concept Nuggets Semaglutide Weight Loss Pills are officially launched in China, and many e-commerce platforms have been launched","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300003":0.9,"300199":0.9,"600276":0.9,"603456":0.9,"688076":0.9,"688117":0.9,"01801":0.9,"002821":0.9,"NVO":0.73},"content_text":"诺和诺德的减肥药诺和盈在国内上市迎来新进展。今日，诺和诺德宣布，全球首个且目前唯一用于长期体重管理的胰高糖素样肽﹣1受体激动剂(GLP-1)周制剂诺和盈正式在中国上市。据悉，诺和盈又被称为“减肥版”司美格鲁肽，能够实现平均约17%的体重降幅，其减重效果可以持续至少2年。诺和诺德透露，目前，诺和盈已在全球超过10个国家和地区上市。截至目前，司美格鲁肽已累积起超过2200万患者暴露年的使用经验。上海部分私立医疗机构表示，诺和盈已经到货，咨询的客户较多。同时，在美团、淘宝、京东等多个平台上均搜索到有诺和盈在销售。今年6月，诺和诺德宣布，国家药品监督管理局批准了诺和诺德研发生产的诺和盈（用于长期体重管理的司美格鲁肽注射液）在中国的上市申请。该药是国内首个获批减肥适应症的注射剂，预计11月中旬会陆续面市，首批药品将进入指定医院、药店、减重中心等。此前，诺和诺德的司美格鲁肽注射剂的降糖适应症于2021年在国内获批。随后7月，竞争对手礼来的替尔泊肽注射液（商品名：穆峰达）长期体重管理新适应症获得国家药监局批准。国内市场前景巨大随着社会经济的快速发展，人们的生活水平上升，肥胖人群增加，国内对减肥药需求涌现。根据Frost&Sullivan统计，中国肥胖人数从2017年的1.9亿人增至2021年的2.3亿人，并预计于2030年达3.3亿人。肥胖可能增加冠心病、糖尿病、高血压等疾病的发病风险，随着肥胖人群的增加和居民对体重管理意识的增强，GLP-1减重市场有望快速放量。因此，减肥药市场前景广阔。全球范围内，高盛的分析团队已经将全球2030年的减肥药市场规模从去年年底的1000亿美元上调至1300亿美元。国内来看，方正证券预计，到2030年，国内GLP-1减肥药市场有望超378.52亿元。此外，减重药物的消费属性强，主要靠个人支付，受医保影响小。投资上，安信国际认为，鉴于今年已有两款进口减肥药在国内获批上市，中国减肥市场有望迎来高速增长阶段。建议关注GLP-1减肥产业链相关标的，原料药厂商如诺泰生物等个股；研发进展靠前的创新药企，如信达生物、恒瑞医药等个股。方正证券建议，原料药布局企业：关注诺泰生物、翰宇药业、圣诺生物、奥锐特等；CDMO：关注凯莱英、九洲药业；创新药布局药企：关注恒瑞医药、博瑞医药、信达生物、乐普医疗、众生药业等。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484509265"}